Publication Abstract from PubMed
Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.
Structural basis of respiratory syncytial virus neutralization by motavizumab.,McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD Nat Struct Mol Biol. 2010 Feb;17(2):248-50. Epub 2010 Jan 24. PMID:20098425[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
